NCT04350736View on ClinicalTrials.gov

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

June 24, 2020

Study Completion Date

July 1, 2020

Conditions
Acute Lung Injury (ALI) Associated With COVID-19Inflammatory Lung Conditions Associated With COVID-19
Interventions
DRUG

TD-0903

Study drug to be administered by inhalation

DRUG

Placebo

Placebo to be administered by inhalation

Trial Locations (1)

M23 9QZ

Theravance Biopharma Investigational Site, Manchester

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY